Literature DB >> 3345573

Enhanced potentiation of cisplatin cytotoxicity in human ovarian carcinoma cells by prolonged glutathione depletion.

P A Andrews1, M A Schiefer, M P Murphy, S B Howell.   

Abstract

We have determined the effect of extended glutathione (GSH) depletion on cis-diamminedichloroplatinum(II) (DDP) cytotoxicity in parent and DDP-resistant human ovarian carcinoma cells. Cells were exposed to 50 microM buthionine sulfoximine (BSO) for 48 h and exposed to DDP for the last 24 h of this time. This treatment protocol sensitized 2008 cells to DDP. The dose modification factor (DMF) defined as IC50 control cells/IC50 GSH depleted cells was 1.6 +/- 0.5 (N = 9). DDP-resistant cells selected by acute, high dose DDP exposure were also sensitized by this treatment; the DMF in the 3-6-fold resistant 2008/DDP cells was 2.4 +/- 1.2 (N = 9). The sensitization was not significantly greater in the resistant cells than in the parent cells (P greater than 0.05). When the rebound of GSH following BSO exposure was reexamined, the GSH levels were found to rise rapidly following trypsinizing and plating. BSO treatment following DDP exposure had no effect on DDP cytotoxicity in 2008 and 2008/DDP cells. These results indicate that simply depleting GSH prior to DDP exposure is not sufficient for sensitizing these cells to DDP. In contrast to the potentiation of nitrogen mustard cytotoxicity, exposure to GSH depletion must be maintained during DDP treatment for enhancement of DDP cytotoxicity to occur.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3345573     DOI: 10.1016/0009-2797(88)90030-0

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  20 in total

1.  Glutathione content is correlated with the sensitivity of lines of PC12 cells to cisplatin without a corresponding change in the accumulation of platinum.

Authors:  K Ikeda; K Miura; S Himeno; N Imura; A Naganuma
Journal:  Mol Cell Biochem       Date:  2001-03       Impact factor: 3.396

2.  Detoxifying enzymes in human ovarian tissues: comparison of normal and tumor tissues and effects of chemotherapy.

Authors:  Z Djuric; V K Malviya; G Deppe; J M Malone; D L McGunagle; L K Heilbrun; B A Reading; W D Lawrence
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

Review 3.  Role of DNA repair in the mechanisms of cell resistance to alkylating agents and cisplatin.

Authors:  P Calsou; B Salles
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin.

Authors:  R D Christen; D K Hom; D C Porter; P A Andrews; C L MacLeod; L Hafstrom; S B Howell
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

5.  Regulation of HSP60 mRNA expression in a human ovarian carcinoma cell line.

Authors:  E Kimura; R E Enns; F Thiebaut; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Modulation of cisplatin sensitivity and growth rate of an ovarian carcinoma cell line by bombesin and tumor necrosis factor-alpha.

Authors:  S Isonishi; A P Jekunen; D K Hom; A Eastman; P S Edelstein; F B Thiebaut; R D Christen; S B Howell
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

7.  Enhancement of the cytotoxicity of cisplatin by the cholecystokinin antagonist MK-329 in a human pancreatic cancer cell line.

Authors:  R Jamshidipour; E B Pinho; D K Hom; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  Cross-resistance and collateral sensitivity to natural product drugs in cisplatin-sensitive and -resistant rat lymphoma and human ovarian carcinoma cells.

Authors:  H Parekh; H Simpkins
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

9.  Cyclophosphamide, cisplatin, and carmustine: pharmacokinetics of carmustine following multiple alkylating-agent interactions.

Authors:  R B Jones; S Matthes; D Kemme; C Dufton; S Kernan
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

10.  Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B.

Authors:  Fardous F El-Senduny; Farid A Badria; Ahmed M El-Waseef; Subhash C Chauhan; Fathi Halaweish
Journal:  Tumour Biol       Date:  2015-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.